Human Molecular Genetics and Genomics — Important Advances and Exciting Possibilities
By Francis S. Collins, M.D., Ph.D., Jennifer A. Doudna, Ph.D., Eric S. Lander, Ph.D., and Charles N. Rotimi, Ph.D.,
The New England Journal of Medicine
| 01. 07. 2021
The breathtaking progress in molecular genetics that has occurred over the past five decades and the transition to genomic medicine would have been difficult to imagine in 1970, when the Institute of Medicine (IOM), now the National Academy of Medicine (NAM), was formed. The term “genomics” hadn’t yet been coined, the tools and technologies that are the foundation of modern biotechnology were in their infancy, and methods for sequencing even a few nucleotides were barely workable.1
The IOM’s early years coincided with paradigm-shifting discoveries related to DNA, as biologic research swiftly incorporated Boyer and Cohen’s recombinant method, Sanger’s DNA-sequencing work, and Mullis’s introduction of polymerase chain reaction (PCR) technology (see timeline). Yet even against this backdrop, the notion of a “big science” endeavor to sequence the human genome seemed radical.
In 1987, the New York Times Magazine characterized the Human Genome Project as the “biggest, costliest, most provocative biomedical research project in history.”2 But in the years between the project’s launch in 1990 and its completion in 2003, genomic technology advanced dramatically. DNA-sequencing throughput increased from 1000...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...